Exclusive Summary

• - Patent protections expired globally and generics have been widely available since 2016, enabling low barriers and rapid market entry.
• - Seasonal influenza causes ~1 billion infections and 290k–650k respiratory deaths annually, with pronounced demand spikes suitable for both stockpiling and retail channels.
• - Listed on the WHO Essential Medicines List and recommended by WHO/CDC/ECDC as first-line oral therapy and post-exposure prophylaxis; 75 mg adult dosing is the standard.
• - US registration serves as a strong quality credential for reliance registrations and institutional tenders amid a crowded generic field.
• - Compared with the originator, generics are typically 50–80% cheaper, delivering clear value in cost-conscious markets.